Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 17 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 524743 | NSE: FISCHER

Fischer Medical Ventures Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 15, 2024, 5:00 pm

Market Cap 3,347 Cr.
Current Price 626
High / Low793/89.8
Stock P/E1,819
Book Value 15.0
Dividend Yield0.00 %
ROCE5.30 %
ROE4.60 %
Face Value 10.0
PEG Ratio19.86

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Fischer Medical Ventures Ltd

Competitors of Fischer Medical Ventures Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Fischer Medical Ventures Ltd 3,347 Cr. 626793/89.81,819 15.00.00 %5.30 %4.60 % 10.0
Emmessar Biotech & Nutrition Ltd 23.5 Cr. 47.164.0/23.327.0 15.60.00 %11.4 %10.6 % 10.0
Cochin Minerals & Rutile Ltd 290 Cr. 370415/23917.9 1982.16 %26.6 %5.82 % 10.0
Archean Chemical Industries Ltd 8,391 Cr. 680838/51631.7 1430.44 %25.8 %19.4 % 2.00
Alufluoride Ltd 389 Cr. 497587/34120.4 1220.60 %25.1 %22.2 % 10.0
Industry Average4,807.69N/A222.44N/AN/A15.2310.71N/A

All Competitor Stocks of Fischer Medical Ventures Ltd

Quarterly Result

MonthMar 2024Jun 2024
Sales20.7910.12
Expenses18.2810.38
Operating Profit2.51-0.26
OPM %12.07%-2.57%
Other Income0.470.74
Interest0.050.13
Depreciation0.180.28
Profit before tax2.750.07
Tax %6.18%271.43%
Net Profit2.59-0.12
EPS in Rs0.48-0.02

Last Updated: October 7, 2024, 8:04 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 23, 2024, 2:28 pm

MonthMar 2023Mar 2024
Sales0.1820.98
Expenses0.1619.12
Operating Profit0.021.86
OPM %11.11%8.87%
Other Income0.000.50
Interest0.020.07
Depreciation0.000.18
Profit before tax0.002.11
Tax %12.80%
Net Profit-0.041.84
EPS in Rs-2.330.34
Dividend Payout %0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2023-2024
YoY Net Profit Growth (%)4700.00%
Change in YoY Net Profit Growth (%)0.00%

Fischer Medical Ventures Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 1 years from 2023-2024 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:%
5 Years:%
3 Years:%
TTM:11556%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:4700%
Stock Price CAGR
10 Years:71%
5 Years:58%
3 Years:92%
1 Year:631%
Return on Equity
10 Years:%
5 Years:%
3 Years:%
Last Year:5%

Last Updated: Unknown

Balance Sheet

Last Updated: September 15, 2024, 1:35 pm

MonthMar 2023Mar 2024
Equity Capital0.1753.50
Reserves-0.4426.74
Borrowings0.571.68
Other Liabilities0.054.40
Total Liabilities0.3586.32
Fixed Assets0.0014.71
CWIP0.000.00
Investments0.001.21
Other Assets0.3570.40
Total Assets0.3586.32

Reserves and Borrowings Chart

Cash Flow

MonthMar 2023Mar 2024
Cash from Operating Activity +-7.59
Cash from Investing Activity +-28.61
Cash from Financing Activity +37.11
Net Cash Flow0.91

Free Cash Flow

MonthMar 2023Mar 2024
Free Cash Flow-0.550.18

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2023Mar 2024
Debtor Days344.72397.88
Inventory Days
Days Payable
Cash Conversion Cycle344.72397.88
Working Capital Days324.44505.40
ROCE %5.30%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%74.91%
FIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%5.07%5.07%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%1.68%1.68%
Public100.00%100.00%100.00%100.00%100.00%100.00%100.00%99.99%100.00%99.99%93.24%18.33%
No. of Shareholders9,0859,1099,0939,1219,1219,0649,0609,1009,1049,0388,9769,285

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24
FaceValue1.00
Basic EPS (Rs.)1.67
Diluted EPS (Rs.)1.10
Cash EPS (Rs.)0.03
Book Value[Excl.RevalReserv]/Share (Rs.)1.52
Book Value[Incl.RevalReserv]/Share (Rs.)1.52
Revenue From Operations / Share (Rs.)0.39
PBDIT / Share (Rs.)0.04
PBIT / Share (Rs.)0.04
PBT / Share (Rs.)0.03
Net Profit / Share (Rs.)0.03
NP After MI And SOA / Share (Rs.)0.03
PBDIT Margin (%)11.35
PBIT Margin (%)10.49
PBT Margin (%)10.16
Net Profit Margin (%)8.86
NP After MI And SOA Margin (%)8.86
Return on Networth / Equity (%)2.29
Return on Capital Employeed (%)2.66
Return On Assets (%)2.15
Long Term Debt / Equity (X)0.01
Total Debt / Equity (X)0.02
Current Ratio (X)18.42
Quick Ratio (X)17.25
Interest Coverage Ratio (X)35.26
Interest Coverage Ratio (Post Tax) (X)28.52
Enterprise Value (Cr.)33382.51
EV / Net Operating Revenue (X)1591.06
EV / EBITDA (X)14006.25
MarketCap / Net Operating Revenue (X)1592.79
Price / BV (X)411.96
Price / Net Operating Revenue (X)1593.09

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Fischer Medical Ventures Ltd as of November 17, 2024 is: 1,280.21

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 17, 2024, Fischer Medical Ventures Ltd is Undervalued by 104.51% compared to the current share price 626.00

Default values used*: Default value of 15 for Book Value is used

Intrinsic Value of Fischer Medical Ventures Ltd as of November 17, 2024 is: 2,452.53

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 17, 2024, Fischer Medical Ventures Ltd is Undervalued by 291.78% compared to the current share price 626.00

Default values used*: Default value of 15 for Book Value is used

Last 5 Year EPS CAGR: 91.57%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock is trading at a low valuation with an average P/B ratio of 0.04 and average Dividend Yield of 10.49%.
  2. The company has higher reserves (13.15 cr) compared to borrowings (1.13 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (10.58 cr) and profit (1.06 cr) over the years.
  1. The stock has a low average ROCE of 2.65%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 414.92, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 371.30, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fischer Medical Ventures Ltd:
    1. Net Profit Margin: 8.86%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 2.66% (Industry Average ROCE: 15.23%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 2.29% (Industry Average ROE: 10.71%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 28.52
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 17.25
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 1 (Industry average Stock P/E: 222.44)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.02
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Fischer Chemic Ltd. is a Public Limited Listed company incorporated on 22/03/1993 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L24231MH1993PLC288371 and registration number is 288371. Currently company belongs to the Industry of Chemicals - Inorganic - Others. Company’s Total Operating Revenue is Rs. 0.00 Cr. and Equity Capital is Rs. 0.17 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Chemicals - Inorganic - Others104, First Floor, Raghuleela Mega Mall, Mumbai Maharashtra 400067fischerchemicltd@gmail.com
https://www.fischerchemic.in
Management
NamePosition Held
Mr. Ravindran GovindanChairman & Managing Director
Mr. Jeena Dineshchandra SutharIndependent Director
Mr. Sanjay Jayantilal JainIndependent Director
Mr. Svetlana RaoWhole Time Executive Director
Mr. Khairy Jamaluddin Abu BakkarIndependent Director
Mr. Jacob ThomasIndependent Director
Mr. Roberto M PagdangananIndependent Director

FAQ

What is the latest intrinsic value of Fischer Medical Ventures Ltd?

The latest intrinsic value of Fischer Medical Ventures Ltd as on 16 November 2024 is ₹1280.21, which is 104.51% higher than the current market price of ₹626.00.

What is the Market Cap of Fischer Medical Ventures Ltd?

The Market Cap of Fischer Medical Ventures Ltd is 3,347 Cr..

What is the current Stock Price of Fischer Medical Ventures Ltd as on 16 November 2024?

The current stock price of Fischer Medical Ventures Ltd as on 16 November 2024 is ₹626.

What is the High / Low of Fischer Medical Ventures Ltd stocks in FY 2024?

In FY 2024, the High / Low of Fischer Medical Ventures Ltd stocks is 793/89.8.

What is the Stock P/E of Fischer Medical Ventures Ltd?

The Stock P/E of Fischer Medical Ventures Ltd is 1,819.

What is the Book Value of Fischer Medical Ventures Ltd?

The Book Value of Fischer Medical Ventures Ltd is 15.0.

What is the Dividend Yield of Fischer Medical Ventures Ltd?

The Dividend Yield of Fischer Medical Ventures Ltd is 0.00 %.

What is the ROCE of Fischer Medical Ventures Ltd?

The ROCE of Fischer Medical Ventures Ltd is 5.30 %.

What is the ROE of Fischer Medical Ventures Ltd?

The ROE of Fischer Medical Ventures Ltd is 4.60 %.

What is the Face Value of Fischer Medical Ventures Ltd?

The Face Value of Fischer Medical Ventures Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Fischer Medical Ventures Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE